The four core outcome domains that should be measured and reported in ALL eczema trials are:
All trials should measure the core domains and measure these using core outcome instruments (where available) as this will enable trials to be compared and combined in meta-analyses. However, the inclusion of core outcomes does not preclude the use of any additional domains, scales or instruments.
Consensus Statement: Schmitt et al. 2014
Eczema Area and Severity Index (EASI) is a validated scoring system that grades the physical signs of atopic dermatitis/eczema.
POEM for patient-reported symptoms
NRS 11 for intensity of itch
Consensus Statement for POEM: Spuls et al. 2017
Patient Oriented Eczema Measure (POEM) is a validated instrument that measures the illness as experienced by the patient.
Numerical Rating Scale (NRS) 11 point for worst itch over the last 24 hours (Yosipovitch 2019)
DLQI (adults), CDLQI (children), IDQoL (infants) for quality of life
DLQI (adults), CDLQI (children), IDQoL (infants) were recommended for the COS at the recent HOME VII meeting for measuring qualty of life.
RECAP* and the ADCT* were recommended for the COS at the recent HOME VII. These instruments will be published in due course and made available via the HOME website.
Centre of Evidence Based Dermatology
University of Nottingham
King's Meadow Campus
Lenton Lane, Nottingham
NG7 2NR, UK
Telephone: +44 115 8232435
Fax: +44 115 8468618
Browser does not support script.